For instance, 87% of glioblastomas have genetic alterations in the TP53/MDM2/MDM4/p14ARF pathway, including TP53 mutations or homozygous deletion (35%), MDM2 amplification (14%), MDM4 amplification (7%), or p14ARF homozygous deletion or mutation (49%) [3]. Here, MDM2 is linked to glioblastoma.